Selena Clearman
Family · Hattiesburg, MSNPI 1518944560
Payments from drug & device makers
Across 520 payments — averaging $13.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$923
- AstraZeneca$798
- Johnson & Johnson$411
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$391
- Lilly USA, LLC$373
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,244100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 138 | $1,379 |
| Novo Nordisk | 67 | $923 |
| AstraZeneca | 23 | $798 |
| Johnson & Johnson | 28 | $411 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $391 |
| Lilly USA, LLC | 23 | $373 |
| Boehringer Ingelheim | 31 | $366 |
| Amgen | 25 | $349 |
| GSK | 39 | $311 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $264 |
| Merck | 11 | $173 |
| Biohaven Pharmaceuticals, Inc. | 9 | $144 |
| Shield Therapeutics Inc | 11 | $142 |
| Pfizer | 7 | $113 |
| Exact Sciences | 5 | $113 |
| Genentech USA, Inc. | 13 | $108 |
| Idorsia Pharmaceuticals US Inc | 6 | $94 |
| Astellas Pharma US Inc | 6 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $83 |
| Abbott | 4 | $80 |
| Nestle Healthcare Nutrition Inc. | 4 | $69 |
| Tris Pharma Inc | 4 | $61 |
| Bayer | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Lundbeck LLC | 2 | $40 |
| Medtronic | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Eisai Inc. | 2 | $27 |
| Mylan Specialty L.p. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Axonics, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,244 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $78,827 |
| MounjaroTirzepatide | 40 | $50,781 |
| JanuviaSitagliptin Phosphate | 40 | $44,408 |
| JardianceEmpagliflozin | 27 | $39,173 |
| LinzessLinaclotide | 25 | $29,752 |
| XareltoRivaroxaban | 28 | $27,903 |
| RybelsusSemaglutide | 15 | $24,887 |
| FarxigaDapagliflozin Propanediol | 19 | $19,364 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $16,346 |
| MyrbetriqMirabegron | 17 | $16,065 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $15,469 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $11,688 |
| EliquisApixaban | 11 | $8,575 |
| Novolog FlexpenInsulin Aspart | 37 | $6,962 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $4,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $923 | $103,71471 claims |
| Lilly USA, LLCMounjaro | $373 | $50,78140 claims |
| MerckJanuvia | $173 | $44,40840 claims |
| Boehringer IngelheimJardiance | $366 | $39,17327 claims |
| AbbVieLinzess, Synthroid | $1,379 | $33,82076 claims |
| Johnson & JohnsonXarelto | $411 | $27,90328 claims |
| AstraZenecaFarxiga | $798 | $19,36419 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $16,06517 claims |
| GSKTrelegy Ellipta | $311 | $15,46917 claims |
| PfizerEliquis | $113 | $8,57511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Hattiesburg
- Erin RobertsHattiesburg$12K
- Victoria FordHattiesburg$11K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.